-
5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid
-
ChemBase ID:
171527
-
Molecular Formular:
C22H32O4
-
Molecular Mass:
360.48708
-
Monoisotopic Mass:
360.2300595
-
SMILES and InChIs
SMILES:
[C@@H]1([C@@H]([C@@H]2[C@H](C1)C/C(=C\CCCC(=O)O)/C2)/C=C/[C@H](C(CC#CC)C)O)O
Canonical SMILES:
CC#CCC([C@@H](/C=C/[C@H]1[C@H](O)C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)C
InChI:
InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1
InChIKey:
HIFJCPQKFCZDDL-ACWOEMLNSA-N
-
Cite this record
CBID:171527 http://www.chembase.cn/molecule-171527.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid
|
|
|
IUPAC Traditional name
|
|
Synonyms
|
(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]pentanoic Acid
|
(1S,2R,3R,5S)-7-[(E)-4-Carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-bicyclo[3.3.0]octane
|
Ciloprost
|
Endoprost
|
Ilomedin
|
ZK 36374
|
Iloprost
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
Data Source
|
Data ID
|
Price
|
TRC
|
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
4.664816
|
H Acceptors
|
4
|
H Donor
|
3
|
LogD (pH = 5.5)
|
2.6708264
|
LogD (pH = 7.4)
|
0.8930734
|
Log P
|
3.5643785
|
Molar Refractivity
|
105.1822 cm3
|
Polarizability
|
39.96046 Å3
|
Polar Surface Area
|
77.76 Å2
|
Rotatable Bonds
|
9
|
Lipinski's Rule of Five
|
true
|
PROPERTIES
PROPERTIES
Safety Information
Product Information
Bioassay(PubChem)
DETAILS
DETAILS
TRC
Toronto Research Chemicals -
I267300
|
A synthetic analogue of Prostacyclin (PGI2) used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and ischemia. It acts through elevation of cAMP by binding to the prostacyclin receptor (IP receptor). Iloprost inhibits the |
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Zamudio, T.P.: Arch. Cardiol. Mex., 77, 198 (2007)
- • Lai, Y. et al.: Am. J. Resp. Crit. Care Med., 178, 188 (2007)
- • Scorza, R. et al.: J. Rheutamol., 24, 1944 (2007)
- • Melillo, E. et al.: Int. J. Microcircul. Clin. Exp., 15, 60 (2007)
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent